2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human renal cell carcinoma cells

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Peptides

6

Inhibitory Antibodies

2

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164734
    Raludotatug Deruxtecan

    R-DXd; DS-6000

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
    Raludotatug Deruxtecan
  • HY-W195984
    Z57346765
    1 Publications Verification

    		 Phosphoglycerate Kinase (PGK) Cancer
    Z57346765 is an inhibitor that targets the ADP-binding pocket of PGK1, with a Kd of 20.9 μM for human PGK1, and exhibits anticancer activity. Z57346765 reduces the activity of the metabolic enzyme PGK1 during glycolysis, regulates lipid peroxidation and cancer cell proliferation, and promotes lipid peroxidation in cervical cancer cells. Z57346765 inhibits the proliferation of cervical cancer and clear cell renal cell carcinoma cells in xenograft mouse models, and induces the expression of genes associated with cell metabolism, DNA replication and cell cycle. Z57346765 is used in research related to cervical cancer, clear cell renal cell carcinoma and breast cancer .
    Z57346765
  • HY-13241A
    Ralimetinib
    Maximum Cited Publications
    15 Publications Verification

    LY2228820

    		 p38 MAPK Autophagy Cancer
    Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
    Ralimetinib
  • HY-P99273
    Vorsetuzumab

    		TNF Receptor Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
    Vorsetuzumab
  • HY-157231A
    HC-5404-Fu

    		PERK Cancer
    HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma .
    HC-5404-Fu
  • HY-P99318
    Sonepcizumab

    LT 1009; Anti-human S1P Recombinant Antibody

    		 LPL Receptor Cancer
    Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
    Sonepcizumab
  • HY-121936
    Yohimbic acid

    		Adrenergic Receptor Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Yohimbic acid is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid exhibits vasodilatory and anticancer activities. Yohimbic acid can be used for the research of cancer, inflammation and cardiovascular disease .
    Yohimbic acid
  • HY-165245
    SBI-183

    		Transmembrane Glycoprotein Cancer
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-172423
    Darlifarnib

    KO-2806

    		 Farnesyl Transferase mTOR VEGFR Cancer
    Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment .
    Darlifarnib
  • HY-142125
    Broussochalcone A

    		Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology Cancer
    Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC50=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .
    Broussochalcone A
  • HY-121352
    Kibdelone C

    		Drug Derivative Cancer
    Kibdelone C is a hexacyclic tetrahydroxanthone natural product and anticancer agent with sub-nanomolar GI50 activity against human SR leukemia and SN12C renal carcinoma cell lines. Kibdelone C disrupts the actin cytoskeleton in human cancer cells, leading to cell contraction and actin stress fiber formation, without direct actin binding, actin polymerization effects, topoisomerase I/II inhibition, or DNA binding. Kibdelone C can be used for the research of leukemia, and renal cell carcinoma .
    Kibdelone C
  • HY-117803
    CP 461 free base

    OSI-461 free base

    		 Apoptosis Cancer
    CP 461 free base (OSI-461 free base) is a novel pro-apoptotic compound with the activity of inhibiting cyclic guanosine monophosphate phosphodiesterase. CP 461 free base exhibits growth inhibitory activity against a variety of human tumor cell lines in vitro. CP 461 free base selectively induces apoptosis in cancer cell lines but has no effect on normal cells. CP 461 free base can be used in the study of renal cell carcinoma, prostate cancer and Crohn's disease .
    CP 461 free base
  • HY-174536
    Human TFE3 mRNA

    		mRNA Cancer
    Human TFE3 mRNA encodes the human transcription factor binding to IGHM enhancer 3 (TFE3) protein, a basic helix-loop-helix domain-containing transcription factor that binds MUE3-type E-box sequences. TFE3 may be involved in chromosomal translocations in renal cell carcinomas and other cancers, resulting in the production of fusion proteins.
    Human TFE3 mRNA
  • HY-183374
    NYM074

    		Carbonic Anhydrase Radionuclide-Drug Conjugates (RDCs) Cancer
    NYM074 is a carbonic anhydrase IX (CAIX) ligand. NYM074 binds specifically to human CAIX to enable targeted radionuclide delivery. NYM074 supports dual radiolabeling with 68Ga for positron emission tomography (PET) imaging and 177Lu for radionuclide applications. NYM074 can be used for the research of clear cell renal cell carcinoma .
    NYM074
  • HY-181270
    RH01504

    		HIF/HIF Prolyl-Hydroxylase Cancer
    RH01504 is a HIF2α inhibitor with a Kd value of 5.42 nM against human HIF2α. RH01504 inhibits the growth of renal cancer cells. RH01504 can be used in research related to renal cell carcinoma .
    RH01504
  • HY-181873
    Rapamycin-butyl ester

    Sirolimus-butyl ester

    		 Drug Derivative Cancer
    Rapamycin-butyl ester (Sirolimus-butyl ester) (Compound 9) is a derivative of Rapamycin (HY-10219). Rapamycin-butyl ester exhibits antiproliferative effects against liver cancer cells and renal cancer cells. Rapamycin-butyl ester can be used in research related to liver cancer and renal cancer .
    Rapamycin-butyl ester
  • HY-P991999
    OM-RCA-01

    		FGFR IFNAR Interleukin Related Cancer
    OM-RCA-01 is an anti-FGFR1 monoclonal antibody with a Kd of 1.59 nM for human FGFR1. OM-RCA-01 inhibits the phosphorylation of FGFR1, blocks FGF-mediated signaling pathways, and suppresses the proliferation of downstream tumor cells. OM-RCA-01 delays tumor growth in lung cancer and renal cancer xenograft models expressing FGFR1. When combined with Nivolumab, OM-RCA-01 enhances the release of IFN-γ and IL-2. OM-RCA-01 is applicable for the research of lung cancer and renal cell carcinoma .
    OM-RCA-01
  • HY-185483
    AMG-172

    		Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Microtubule/Tubulin Cancer
    AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal anti-CD27L antibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .
    AMG-172
  • HY-P992395
    JNJ-64164711

    JNJ-711

    		 TNF Receptor NF-κB Cancer
    JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .
    JNJ-64164711
  • HY-183583
    HIF-2α-IN-18

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC50 of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and PDK1. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma[1].
    HIF-2α-IN-18
  • HY-P992365
    HFB101110

    		CCR Cancer
    HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
    HFB101110
  • HY-P992322
    BAY-79-4620 Antibody

    		ADC Antibody Carbonic Anhydrase Cancer
    BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma .
    BAY-79-4620 Antibody
  • HY-185484
    MDX-1203

    BMS-936561

    		 Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Cancer
    MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma .
    MDX-1203
  • HY-P11737
    IPM-N001

    		Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase Cancer
    IPM-N001 is a carbonic anhydrase IX (CAIX) ligand with a Kd value of <0.0337 nM for hCAIX. When radio-conjugated with 68Ga, IPM-N001 serves as a CAIX-targeted radionuclide tracer. [ 68Ga]Ga-IPM-N001 exhibits excellent tumor uptake and significantly improves the tumor-to-background ratio in PET/CT imaging studies using OS-RC-2 tumor-bearing mice. IPM-N001 can be used for the research of clear cell renal cell carcinoma .
    IPM-N001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: